Speakers

Personal Information

Dr. Killeen joined Matrivax as Chief Scientific Officer in 2009. He has extensive training in the fields of vaccinology, molecular biology, microbiology, protein chemistry, and immunology. Dr. Killeen’s experience includes identifying and leading the in-licensing effort of the rotavirus vaccine candidate 89-12, now Rotarix®, a blockbuster vaccine commercialized by GSK. Prior to Matrivax, he led the bacterial vaccine R&D program at AVANT-Celldex. Dr. Killeen commercialized two diagnostic tests at IDEXX Inc. and directed 7 vaccine candidates into Phase 1 and 2 clinical trials at Celldex and Matrivax. He has authored >30 peer-reviewed articles, chapters, and reviews, and is the inventor on multiple patents. He is long standing member of the URI Dean’s Advisory Council and a former Human Vaccines and Immunotherapies editor. Dr. Killeen was the principal investigator on vaccine related grants and contracts exceeding $10 million. Dr. Killeen holds a Ph.D. in microbiology from the University of Rhode Island and completed a post-doctoral fellowship at Harvard Medical School in molecular genetics and protein toxin chemistry.